Reducing the antifungal drugs consumption in the ICU
|
|
- Arnold Byrd
- 6 years ago
- Views:
Transcription
1 Reducing the antifungal drugs consumption in the ICU Philippe Montravers Département d Anesthésie et Réanimation Chirurgicale CHU Bichat Claude Bernard Pole TCAUR, HUPNVS Assistance Publique-Hôpitaux de Paris Université Paris VII Denis Diderot Sorbonne Cité Paris, France
2 Disclosures Speaker: Astellas, Astra Zeneca, Basilea, Cubist, Gilead, MSD, The Medicines Company, Pfizer Advisory board: Astellas, Astra Zeneca, Cubist, MSD, Parexel, Tetraphase, The Medicines Company, Pfizer
3 Candida is the predominant fungal pathogen in the ICU setting Fungal infections in the ICU 7% 5% 88% Global surveillance study of 13,796 adults in 1265 ICUs in 75 countries Candida responsible for 88% of fungal infections (n=963) 89% in Europe (n=633) 85% elsewhere (n=330) Candida Aspergillus Vincent JL et al. JAMA. 2009;302:2323 9
4 Candida is the 3 rd most common cause of ICU infections globally Proportion of microorganismpositive isolates (%) ,5 19, Pseudomonas species Global data* 17,0 17,0 16,0 12,7 10,8 10,2 Candida Other Gram- Escherichia coli Klebsiella species S epidermidis MRSA * 7087 patients; 69.8% with microorganism-positive isolates ** Other than E. coli, Enterobacter, Klebsiella, Pseudomonas, or Acinetobacter Vincent JL et al. JAMA. 2009;302:2323 9
5 ...and the 2 nd most common cause of ICU infections in Western Europe Proportion of microorganismpositive isolates (%) Western European data* 19,6 18,5 18,2 17,1 17,1 11,2 9,7 8,7 Candida Other Gram- Escherichia coli Pseudomonas species S epidermidis Klebsiella species MRSA * 3683 patients; 72.7% with microorganism-positive isolates ** Other than E. coli, Enterobacter, Klebsiella, Pseudomonas, or Acinetobacter Vincent JL et al. JAMA. 2009;302:2323 9
6 Trends in the incidence in candidemia episodes incidence of candidemia episodes/ patient-days/year; DDD's of fluconazole ~ 100 pts/days % Bassetti M. BMC Infect Dis 2006;6: % Lortholary O. Intensive Care Med 2014;40:
7 Many ways to prescribe antifungal agents Prophylaxis: to prevent development of invasive fungal infections during periods of risk Pre-emptive or presumptive therapy: early treatment of the infection with use of clinical, laboratory, or radiologic surrogate markers of disease in high-risk hosts before clinical signs and symptoms or full-blown disease develops Empiric therapy: for critically ill patients with risk factors for invasive candidiasis, no other known cause of fever, based on clinical assessment of risk factors, serologic markers for invasive candidiasis, and/or culture data from non sterile sites Directed therapy: for microbiologically or histologically documented infection Ostrosky-Zeichner L. Crit Care Med 2006, 34: Bow EJ et al. Can J Infect Dis Med Microbiol 2010;21: e Cornely O et al. Clin Microbiol Infec 2012; 18 Suppl 7: Pappas PG, et al. Clin Infect Dis 2016;62: e1-50
8 Polyens : Complexes with Ergosterol Triazoles : Interruption of the sterol synthesis Echinocandins : Inhibition of glucane synthesis
9 Antifungal therapy: recent trends Echinocandins Azoles Amphotericin B Leroy N= Azoulay 2008 N= Bassetti N= Leroy N= Expressed as proportions of the total number of prescriptions Leroy O et al. Crit Care Med 2009;37: Azoulay E et al. Crit Care Med 2012;40: Bassetti M et al. Intensive Care Med 2015;41: Leroy O et al. Ann Intensive Care 2016;6:2
10 Recommended drugs for candidemia/invasive candidiasis Guidelines Recommendation ESCMID SITI/ISC ITALIC Middle East Expert panel 4 Echinocandins/Liposomal amphotericin B /Voriconazole Echinocandins/Lipid amphotericin B/Azoles Echinocandins Echinocandins/Liposomal amphotericin B /Azoles IDSA Echinocandins/Fluconazole ESCMID, European Society of Clinical Microbiology and Infectious Diseases; IDSA, Infectious Disease Society of America; ISC, International Society of Chemotherapy; ITALIC, Italian consensus for invasive candidiasis mangement; SITI, Italian Society of Intensive Care 1. Cornely OA, et al. Clin Microbiol Infect 2012;18(Suppl 7): Bassetti M, et al. Intensive Care Med 2013;39: Scudeller L, et al. Infection 2014;42: Alothman AF, et al. J Infect Public Health 2014; 7: Pappas PG et al. Clin Infect Dis 2016;62:e1-50
11 Why decreasing the prescription of antifungal agents? Poor justification/quality of the prescription Ecological issues Emergence of resistance Cost containment
12 Poor justification/quality of the prescription Madrid December 2010 to January 2011 One hospital 100 adult inpatients Systemic antifungals prescribed Empirical (42%) Pre-emptive (20%) Targeted treatment (20%) Cultures obtained in 78.8% of the prescriptions Positive fungal cultures in 56.7% Inappropriate therapy (agent, dose) in 57% of the cases Antifungals were unnecessary in 16% of cases Valerio M et al. J Antimicrob Chemother 2014; 69:
13 Poor justification of the prescription France 169 ICUs a single day (dec 8 th 2008) 2,047 patients recruited 1,893 patients without antifungal agents (AF) 154 (7.5%) patients received systemic AF Fluconazole (60%) caspofungin (24%) voriconazole (8%) liposomal Ampho B (5%) 100 (65%) pts without definite invasive fungal infection (IFI) 54 patients with documented IFI Mortality rate at Day 28 19% in patients without AF therapy 20% in patients receiving AF therapy without definite IFI Azoulay E et al. Crit Care Med 2012; 40:
14 Poor justification of the prescription France 87 ICUs (Oct 2012-Oct 2013) prospective registery 835 patients analyzed receiving antifungal agents (AF) 291 documented therapy for proven invasive candidiasis 544 empiric systemic AF for suspected invasive candidiasis 112 secondarily confirmed invasive candidiasis 432 (432/544=79%) finally non-documented infections Duration of antifungal therapy 12±10 days Leroy O et al. Ann. Intensive Care 2016;6:2
15 C. albicans rate Trends in the incidence in candida species 182 episodes of candidemia Single centre study Fluconazole usage (DDD/year) Candida albicans and Candida non-albicans isolates rates during the study period. Bassetti M. BMC Infect Dis 2006;6:21
16 Proportion of isolates (%) Trends in the incidence in candida species Single centre study ,712 positive samples from 5,360 ICU patients 2,403 candida isolates (+29% of candidas over the study period) % +11% C albicans C glabrata C parapsilosis C tropicalis C krusei C non-albicans Bailly S. J Infect 2016;71:
17 13% Changes in epidemiology of candidemia: Importance of prior antifungal exposure 2,289 cases Without previous AF exposure 3% 10% 18% C. albicans C. glabrata 56% C. parapsilosis C. tropicalis C. krusei 14% 13% 31% 8% 13% 29% 36% 21% 35% Lortholary O et al. Antimicrob. Agents Chemother. 2011; 55 :
18 Proportion of resistance in candidemia 995 episodes of candidemias from 5 tertiary care teaching hospitals in Italy and Spain (CLSI breakpoints) % of resistance Caspofungin Fluconazole Voriconazole C albicans (n=558) 0% 1.4% 1.2% C parapsilosis (n=186) 2.7% 2.7% 1% C glabrata (n=79) 0% 45.6% NA C tropicalis (n=89) 0% 4.5% 3.4% Bassetti M.J Clin Microbiol 2013;51: episodes of candidemias from 30 Belgium hospitals (EUCAST breakpoints) % of resistance Anidulafungin Fluconazole Voriconazole C albicans (n=169) 0% 3.9% 3.9% C parapsilosis (n=186) 0%* 5.6% 5.6% C glabrata (n=27) 1% 11.3% NA C tropicalis (n=19) 0% 20% 20% * All strains were classified as intermediate susceptible Trouve C. Eur J Clin Microbiol Infect Dis 2016;nov 17, Epub
19 Caspofungin consumption (DDD/1000HD) MIC of Caspofungin for C. glabrata Increased resistance toward echinocandins Caspofungin Consumption (DDD/1000HD) Predicted MIC of Caspofungin for C. glabrata 0,18 0,16 0,14 0,12 0,1 0,08 0,06 0,04 0,02 0 Increased caspofungin use correlated significantly with increased MIC values of: C. parapsilosis isolates (P=0.01) 3 months later, C. glabrata isolates (P=0.001) 2 months later C. albicans (P=0.02) 7 months later Bailly S. J Infect 2016;71:
20 Drug use (DDDs/1000 HD) Trends in the use of antifungal agents Single centre study in ICU patients Antifungal use determined in Defined Daily Dose (DDD) per 1000 hospital Days % +298% +11% -58% Amphotericin B Fluconazole Echinocandins All Antifungal agents Bailly S. J Infect 2016;71:
21 Increased resources use Catalonia Spain- 52 acute care hospitals assessed in daily doses (DDD)/100 patient-days Antifungal consumption : intensive care units: DDD/1000-patient-days medical departments: 3.08 surgical departments: % increased antifungal consumption % In ICUs with a trend towards substitution of old agents by the new ones Upward trend both for azoles and echinocandins. Fondevilla E et al. Expert Rev Anti Infect Ther. 2016;14: Montreal Canada 10 years survey ( ) - University hospital 2.97-fold increase in the number of DDD/1000 patient-days 2.97-fold increase in the number of days of therapy /1000 patient-days Guillot J et al. J Pediatr Pharmacol Ther 2014; 19: Madrid December 2010 to January 2011 One hospital Costs 2,194 per patients 50,536 possible savings in case of optimized therapy (-23%) Valerio M et al. J Antimicrob Chemother 2014; 69:
22 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Valerio M et al. J Antimicrob Chemother 2014; 69:
23 Non-Specific Acute renal failure Specific Risk factors for invasive candidiasis Central venous catheter placement Total parenteral nutrition ICU stay Severity of sepsis Diabetes and immunosuppression Prolonged broad-spectrum antibacterial therapy Recurrent abdominal surgery (laparoscopies included) Gastro-intestinal tract perforations (recurrent perforations and/or perforations untreated within 24 h - control of upper GI perforations is more problematic) Gastro-intestinal anastomosis leakage (more severe if the leakage is in the upper GI tract, in particular that involving the esophagus) Multifocal colonization by Candida spp. Bassetti M et al. Intensive Care Med 2013;39:
24 Predictive scores of candida isolation Dupont H.Crit Care Med 2003;31:752 7 Leon C. Crit Care Med. 2006;34:730 7 Ongoing antimicrobial therapy 48 h Surgery on ICU admission Per-operative cardiovascular failure Severe sepsis Cardiovascular failure Total parenteral nutrition Upper gastrointestinal tract perforation Multifocal Candida species colonization Paphytou NI. Med Mycol. 2005;43: Diabetes mellitus New onset hemodialysis Total parenteral nutrition Broad spectrum antibiotics Dupont H. Crit Care 2015;19:60 Length of stay 48 h before surgery Per-operative cardiovascular failure Generalized peritonitis Upper gastrointestinal tract perforation Ostrosky-Zeichner L. Eur J Clin Microbiol Infect Dis 2007;26: Antibiotic use day 1-3 Central venous catheter Surgery Immunosuppressive use Pancreatitis Total parenteral nutrition Dialysis Steroid use
25 Additional tools for assessing candidiasis Rapid diagnostic tests Conventional mycologic tests Biomarkers Previous candida colonization Cornely OA, et al. Clin Microbiol Infect 2012;18(Suppl 7):19 37 Bassetti M, et al. Intensive Care Med 2013;39: Scudeller L, et al. Infection 2014;42: Alothman AF, et al. J Infect Public Health 2014; 7:6-19 Ruhnke M. Clin Microbiol Infect 2014; 20 (Suppl. 6): Pappas PG et al. Clin Infect Dis 2016;62:e1-50
26 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Valerio M et al. J Antimicrob Chemother 2014; 69:
27 C albicans C glabrata C krusei C parapsilosis C tropicalis Spectrum of activity against yeasts Polyenes Fluconazole Voriconazole EChinocandins
28 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Is it the first option recommended by guidelines? Valerio M et al. J Antimicrob Chemother 2014; 69:
29 Recommended drugs for candidemia/invasive candidiasis Guidelines Recommendation ESCMID SITI/ISC ITALIC Middle East Expert panel 4 Echinocandins/Liposomal amphotericin B /Voriconazole Echinocandins/Lipid amphotericin B/Azoles Echinocandins Echinocandins/Liposomal amphotericin B /Azoles IDSA Echinocandins/Fluconazole ESCMID, European Society of Clinical Microbiology and Infectious Diseases; IDSA, Infectious Disease Society of America; ISC, International Society of Chemotherapy; ITALIC, Italian consensus for invasive candidiasis mangement; SITI, Italian Society of Intensive Care 1. Cornely OA, et al. Clin Microbiol Infect 2012;18(Suppl 7): Bassetti M, et al. Intensive Care Med 2013;39: Scudeller L, et al. Infection 2014;42: Alothman AF, et al. J Infect Public Health 2014; 7: Pappas PG et al. Clin Infect Dis 2016;62:e1-50
30 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Is it the first option recommended by guidelines? Is the dosage correct according to the bodyweight, the liver and renal function and potential interaction with other drugs? Valerio M et al. J Antimicrob Chemother 2014; 69:
31 DALI Fluconazole results Fluconazole Number of patients 15 Age (yrs) 56 (44-82) Weight (kg) 82 (80-90) Male sex 11 (73) Dose received (mg) 400 ( ) Dose (mg/kg) 4.9 ( ) APACHE II score 22 (10-30) DALI Buijk (surgical pts) Sobue (volunteers 800 mg/d) AUC (259) 409 ( ) 608 (118) C max 20 (14) 25 (22-28) 34 (6) C min 14 (11) 15 (10-20) 20 (NR) Buijk SLCE. Intensive Care Med.27: Sobue S. Br J Clin Pharmacol.58: Target fauc 0-24 /MIC 100 was reached in 86% patients when the assumed MIC was 1 mg/l If MIC 2 mg/l (clinical breakpoint) and 4 mg/l (clinical breakpoint for resistance using EUCAST methods and susceptible dose-dependent using CLSI methods) fauc 0-24 /MIC 100 was reached in only 67% and 13% of patients Sinnollareddy MG et al. Crit Care. 2015;19(1):33
32 DALI Echinocandins results Anidulafungin Caspofungin Number of patients 9 6 Age (yrs) 51 (41-66) 62 (58-72) Weight (kg) 81 (76-92) 80 (75-85) Male sex 7 (78) 5 (71) Dose received (mg) (L dose) AUC; mg.h/l Plasma Peak; µg/ml Anidulafungin Caspofungin Chen SC et al. Drugs 2011;71:11-41 Dose (mg/kg) NA NA APACHE II score 18 (15-32) 22 (20-26) Parameters DALI Caspofungin Wurthwein (general pts) Stone (volunteers) DALI Anidulafungin Liu et al (volunteers) Liu et al (volunteers) AUC (53) (34) 97.0 (87-109) 55 (28) 93.0 (41) (22) C max 3.9 (55) 13.8 (31) 12.1 (11-13) 3.9 (29) 7.7 (56) 7.0 (22) C min 1.5 (57) 4.2 (2.56) 1.4 ( ) 1.8 (30) 3.0 (44) 3.1 (25) Wurthwein G. Antimicrob Agents Chemother.57: Stone JA. Antimicrob Agents Chemother.46: Liu P et al. Antimicrob Agents Chemother 2013;57: Sinnollareddy MG et al. Crit Care. 2015;19(1):33
33 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Is it the first option recommended by guidelines? Is the dosage correct according to the bodyweight, the liver and renal function and potential interaction with other drugs? Is the antifungal adjusted after microbiological results (microorganism identification, antifungal susceptibility tests and indirect tests) were available? Valerio M et al. J Antimicrob Chemother 2014; 69:
34
35 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Is it the first option recommended by guidelines? Is the dosage correct according to the bodyweight, the liver and renal function and potential interaction with other drugs? Is the antifungal adjusted after microbiological results (microorganism identification, antifungal susceptibility tests and indirect tests) were available? Is de-escalatation performed when possible? Is intravenous switched to oral performed when possible? Valerio M et al. J Antimicrob Chemother 2014; 69:
36
37 Key issues to address for optimizing antifungal therapy Does the patient need an antifungal therapy? Does the antifungal cover the suspected fungi Is it the first option recommended by guidelines? Is the dosage correct according to the bodyweight, the liver and renal function and potential interaction with other drugs? Is the antifungal adjusted after microbiological results (microorganism identification, antifungal susceptibility tests and indirect tests) were available? Is intravenous switched to oral or de-escalatation performed when possible? Is the duration of therapy correct according to the guidelines? Valerio M et al. J Antimicrob Chemother 2014; 69:
38 Implementation of stewardship programs France Nivoix Y et al. J Antimicrob Chemother 2012;67: Mondain V et al. Infection 2013;41:621-8 UK Micallef C et al. J Antimicrob Chemother 2015;70: USA Aitken Sl et al. Ann Pharmacother 2014;48: Huang AM et al. Clin Infect Dis 2013;57: Spain Valerio M et al. Clin Microbiol Infect 2015; 21: 492.e1 492.e9
39 Conclusions Need for cautious use of antifungal agents 65 up to 79% of ICU patients who receive AF agents do not need them Short course or no initiation of AF therapy could be decided in some cases without endangering these patients Major ecological and economic consequences of overuse of AF agents Few data in the ICU setting Best approach through stewardship programs
ESCMID Online Lecture Library. by author
What is the best antifungal strategy for severe intra-abdominal infections? Philippe Montravers MD, PhD Anaesthesia and Surgical ICU Bichat Claude Bernard Hospital Assistance Publique Hopitaux de Paris
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More informationAntifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul
Antifungal Stewardship Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul 1 2 Objectives What do we know? Invasive Candida and Aspergillosis Impact
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationDr Eggimann collaborated in several industrysponsored. clinical trials since Talk ID: year old BMI 41 Transferred for septic shock
Suggestions to prevent Candida infections Dr Philippe Eggimann, PD&MER Service de Médecine Intensive Adulte www.soins-intensifs.chuv.ch Anything I say can be highly biased Dr Eggimann collaborated in several
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationThe EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit?
Editorial The EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit? Michael Osthoff 1,2, Nina Khanna 1,2, Martin Siegemund 3 1 Division of Infectious
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More information1 Guidelines for the Management of Candidaemia
1 Guidelines for the Management of Candidaemia LIVERPOOL CLINICAL LABORATORIES GUIDELINE FOR THE MANAGEMENT OF CANDIDAEMIA IN NON-NEUTROPENIC ADULT PATIENTS AND PROPHYLAXIS/PRE-EMPTIVE TREATMENT IN HIGH
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationPrevention and management of antifungal-resistant infections in the ICU
Prevention and management of antifungal-resistant infections in the ICU Adrian Brink Clinical Microbiologist, Ampath National Laboratory Services, Milpark Hospital, Johannesburg and Associate Senior Lecturer,
More informationEfficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis
Efficacy of a Novel Echinocandin, CD0, in a Mouse Model of Azole-Resistant Disseminated Candidiasis L. Miesel, K-Y Lin, J. C. Chien, M. L. Hsieh, V. Ong, and K. Bartizal Eurofins Panlabs, Taipei, Taiwan
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationAnidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies
Received: 1 February 2017 Revised: 11 May 2017 Accepted: 11 May 2017 DOI: 10.1111/myc.12641 ORIGINAL ARTICLE Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Clinical Infectious Diseases Advance Access published July 9, 2014 MAJOR ARTICLE FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia Nicholas D. Beyda, 1 Julie John, 1 Abdullah
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationTOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018
TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01 Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma,
More informationBlood stream candidiasis. R. Demeester, D. Famerée, B. Guillaume, JC. Legrand CHU Charleroi SBIMC 8th of November 2012
Blood stream candidiasis R. Demeester, D. Famerée, B. Guillaume, JC. Legrand CHU Charleroi SBIMC 8th of November 2012 62-year-old man: clinical history Fever for 10 days with peaks above 39 C, cough, orthopnea
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationCD101: A Novel Echinocandin
CD101: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer TIMM Belgrade, Serbia October 8, 2017 1 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics 2 Cidara
More informationUpdate on Antifungal Stewardship
Update on Antifungal Stewardship Dr Jacqueline Sneddon, MRPharmS Scottish Antimicrobial Prescribing Group Antimicrobial Management Team event 7 th November 2017 ANTIFUNGAL STEERING GROUP CHAIR Prof Brian
More informationAntifungal Treatment in Neonates
Antifungal Treatment in Neonates Irja Lutsar University of Tartu, Estonia Lisbon, 12. October 2015 Prevalence of invasive fungal infections in NeoINN database 2005-2014 UK; 2012-2014 Estonia & Greece 1
More informationConvegno Nazionale Terapia Antibiotica dei patogeni. Le candidemie oggi: una gestione articolata
Convegno Nazionale Terapia Antibiotica dei patogeni multiresistenti (MDRO): una sfida aperta Ferrara, 15 Giugno 2018 Le candidemie oggi: una gestione articolata Michele Bartoletti Infectious Diseases Unit
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationEarly Diagnosis and Therapy for Fungal Infections
Early Diagnosis and Therapy for Fungal Infections Debra Goff PharmD, FCCP Clinical Associate Professor Infectious Disease Specialist The Ohio State University Medical Center Columbus Ohio, USA The Ohio
More informationUpdate zu EUCAST 2012 Cornelia Lass-Flörl
Update zu EUCAST 2012 Cornelia Lass-Flörl Frühjahrstagung 2012 Paul-Ehrlich-Gesellschaft Sektion Antimykotische Chemotherapie Bonn, 4./5. Mai 2012 Agenda 1. Breakpoints 2. Rationale documents and technical
More informationTerapia empirica e mirata delle infezioni invasive da Candida
Terapia empirica e mirata delle infezioni invasive da Candida Francesco Menichetti, MD Head, Infectious Diseases Unit Ospedale Nuovo Santa Chiara Pisa, Italy Corso Avanzato di Terapia Antibiotica X Edizione
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationEUCAST-AFST Available breakpoints 2012
EUCAST-AFST Available breakpoints th NSMM meeting Göteborg, Sweden October th EUCAST-AFST documents Reference Methods Yeast E.DEF. () TN- E.DEF. (CMI epub July) E.DEF. () TN- E.DEF. () Breakpoints Compound
More informationMay 11, Ceftriaxone for MSSA. Daptomycin Dosing Weight. Candidiasis Treatment
Diagnostics and Debates: An Update on Rapid Diagnostic Testing and Current Controversies in Infectious Diseases Nicholas Torney, PharmD, BCPS Derek Vander Horst, PharmD Munson Medical Center WMSHP Annual
More informationIsolates from a Phase 3 Clinical Trial. of Medicine and College of Public Health, Iowa City, Iowa 52242, Wayne, Pennsylvania ,
JCM Accepts, published online ahead of print on 26 May 2010 J. Clin. Microbiol. doi:10.1128/jcm.00806-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationReceived 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1765 1771 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02517-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Multicenter
More informationFungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy
MAJOR ARTICLE Fungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy Jan J. De Waele, 1 D. Vogelaers, 2 S. Blot, 1 and F. Colardyn 1 1 Intensive Care Unit and
More informationScottish Medicines Consortium
Scottish Medicines Consortium anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 09 May 2008 The Scottish Medicines Consortium (SMC) has
More informationAntifungal susceptibility testing: Which method and when?
Antifungal susceptibility testing: Which method and when? Maiken Cavling Arendrup mad@ssi.dk SSI & Juan Luis Rodriguez Tudela jlrtudela@isciii.es ISCIII Agenda Summary of current standards and selected
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationReceived 4 August 2010/Returned for modification 23 October 2010/Accepted 19 November 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 561 566 Vol. 55, No. 2 0066-4804/11/$12.00 doi:10.1128/aac.01079-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Candida
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationCandida glabrata: an emerging pathogen in Brazilian tertiary care hospitals
Medical Mycology January 2013, 51, 38 44 Candida glabrata: an emerging pathogen in Brazilian tertiary care hospitals ARNALDO L. COLOMBO *, MARCIA GARNICA, LUIS FERNANDO ARANHA CAMARGO, CLOVIS ARNS DA CUNHA,
More informationThe antibiotic dose and the obese ICU patient
The antibiotic dose and the obese ICU patient Philippe Montravers, M.D., Ph.D. Anaesthesia and Surgical ICU CHU Bichat Claude Bernard Assistance Publique-Hôpitaux de Paris INSERM UMR 1152 University Paris
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationLa terapia empirica nelle infezioni micotiche
La terapia empirica nelle infezioni micotiche Spinello Antinori Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco Castellanza, 5 ottobre 2013 Empiric antifungal therapy: definition The receipt
More informationCandidemia: Lessons learnt from Asian studies for intervention
Candidemia: Lessons learnt from Asian studies for intervention Dr Methee Chayakulkeeree Associate Professor Division of Infectious Diseases and Tropical Medicine Faculty of Medicine iriraj Hospital Mahidol
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationReceived 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1942 1946 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02434-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Activity
More informationWertigkeit der Diagnostik von Pilzinfektionen an der Intensivstation
Wertigkeit der Diagnostik von Pilzinfektionen an der Intensivstation Cornelia Lass-Flörl Division für Hygiene und medizinische Mikrobiologie MUI Innsbruck Key message... 1. Surveillance-Kulturen spielen
More information8/24/2015. Objectives (Pharmacists) Azoles: Mechanism of action. Objectives (Technicians)
Objectives (Pharmacists) Invasive fungal infections: What to do if there s a fungus among us Nick O Donnell, PharmD, BCPS Infectious Diseases Pharmacotherapy Fellow List three important interactions and
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationInfezioni intraddominali e candidiasi invasiva G. Sganga
Infezioni intraddominali e candidiasi invasiva G. Sganga Department of Surgery Division of General Surgery and Organ Transplantation Catholic University of Sacred Heart Policlinico A. Gemelli, Rome, Italy
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia
16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,
More information1* 1. Vijaya S. Rajmane, Shivaji T. Mohite
ISSN 2231-4261 ORIGINAL ARTICLE Comparison of the VITEK 2 Yeast Antifungal Susceptibility ing with CLSI Broth Microdilution Reference for ing Four Antifungal Drugs against Candida species Isolated from
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationSupplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to
Supplementary Materials to the Manuscript: Polymorphisms in TNF-α Increase Susceptibility to Intra-abdominal Candida Infection in High Risk Surgical ICU Patients A. Wójtowicz, Ph.D. 1, F. Tissot, M.D.
More informationTherapeutic Options: Where do we stand? Where do we go?
Therapeutic Options: Where do we stand? Where do we go? Oliver A. Cornely MD, FACP, FIDSA, FAAM Chair, Translational Research, CECAD Cluster of Excellence Deputy Head, Division of Infectious Diseases Director,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationOutcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata and Candida krusei
J Antimicrob Chemother 211; 66: 375 3 doi:1.193/jac/dkq446 Advance Access publication 8 December 21 Outcomes with micafungin in patients with candidaemia or invasive candidiasis due to Candida glabrata
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AAP. See American Academy of Pediatrics (AAP) Acyclovir dosing in infants, 185 187 American Academy of Pediatrics (AAP) COFN of, 199 204 Amphotericin
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationEvaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
J Antimicrob Chemother 2014; 69: 1993 1999 doi:10.1093/jac/dku053 Advance Access publication 21 March 2014 Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed
More informationThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Clinical Medicine Insights: Therapeutics Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Impact of the New Clinical Breaking Points Proposed
More informationA research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts
Intensive Care Med (2013) 39:2092 2106 DOI 10.1007/s00134-013-3109-3 ORIGINAL Matteo Bassetti Monia Marchetti Arunaloke Chakrabarti Sergio Colizza Jose Garnacho-Montero Daniel H. Kett Patricia Munoz Francesco
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationTable 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 2008-2011 Part 1: The Yeasts In this article, an update of recent changes to the CLSI antifungal standards for susceptibility testing of yeasts is presented. We
More informationEpidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review
Epidemiology and Outcomes of Candidaemia among Adult Patients Admitted at Hospital Universiti Sains Malaysia (HUSM): A 5-Year Review Haydar A a a Department of Internal Medicine, Kulliyyah of Medicine,
More information